Inito raises $29M to expand AI-powered at-home diagnostics
The Series B round was led by Bertelsmann India Investments, with participation from existing investor Fireside Ventures, bringing Inito’s total equity capital to $45 million.
Inito, an at-home diagnostics startup, on Thursday raised $29 million in Series B funding as it seeks to broaden its hormone-testing platform beyond fertility and push deeper into clinical-grade tests built with synthetic, AI-engineered antibodies.
The Series B round was led by Bertelsmann India Investments, with participation from existing investor Fireside Ventures, bringing Inito’s total equity capital to $45 million. The Bengaluru-based company, founded by Aayush Rai and Varun AV, has analysed more than 30 million hormone data points since its 2021 launch.
Inito’s device measures four key fertility hormones—FSH, Estrogen, LH and PdG (a urine metabolite of progesterone)—and feeds the results into AI models that track patterns and ovulation. After helping users track tens of thousands of pregnancies, the company is seeking to build a broader portfolio of at-home diagnostic tests for hormones and other biomarkers.
The fresh capital will accelerate Inito’s work on designing diagnostic tests in silico, reducing reliance on animal-based antibody development and speeding up product cycles. The company aims to expand into areas such as testosterone, thyroid function, vitamins and metabolic health.
The new funding underscores rising investor interest in diagnostics innovation that blends biotech with computational modelling. Conventional antibodies, the backbone of medical tests for decades, are grown in animals and screened manually—an expensive, slow, and error-prone process. Inito said its shift toward computational protein design allows it to create synthetic antibodies with higher sensitivity and consistency, enabling tests that weren’t previously possible outside of labs.
“The future of healthcare lies at the intersection of deep science, AI, and personal wellness—and that’s exactly where Inito is leading,” said Swati Murarka, Principal at Bertelsmann India Investments. Fireside Ventures partner Kannan Sitaram said the company has evolved from “a breakthrough idea into a trusted women’s health brand” built on clinical precision.
With more than 20 patents and teams in Dubai, Bengaluru and London, Inito joins a wave of startups building consumer health tools that promise lab-quality insights from home—a segment that has drawn global attention as patients seek faster, cheaper and more convenient alternatives to clinic visits.